Regulation of hepatic function by brain neuropeptides

Abstract

Key Words: liver/physiology, thyrotropin releasing hormone, corticotropin releasing factor, neuropeptide Y, central nervous system, bombesin, β-endorphin, D-Ala-Met enkepalinamide

TEXT

Since the central nervous system was first demonstrated to be involved in regulation of gastric function by Pavlov[1], and Selye[2] established the stress theory that physicopsychiatric stress altered physiological functions[3], electrical stimulation or lesion of specific brain nuclei identified specific sites in the hypothalamus, limbic system, and medulla that influence gastrointestinal functions. A plethora of peptides have been characterized in the brain by immunohistochemical and molecular biological techniques[4]. The development of retrograde tracing techniques combined with immunohistochemistry reveals that these peptides are localized in the nerve fibers or cell bodies of the hypothalamus and medulla which are important sites for autonomic nervous outflow to the gastrointestinal tract[5,6]. Based on these studies, Taché first reported the effect of central neuropeptides in regulation of gastric functions[7,8]. Since then, more than 40 peptides have been examined and it is well established that many neuropeptides, such as thyrotropin releasing hormone (TRH), corticotropin releasing factor (CRF), neuropeptide Y (NPY), bombesin and somatostatin, mediate a central nervous system induced stimulation or inhibition of gastrointestinal function[9,10]. On the other hand, the liver is also richly innervated[11,12] and retrograde tracing technique has revealed hepatic innervation through the vagus originating in the medulla[13], where abundant neuropeptides exist. This review introduces the current knowledge of central nervous system regulation of hepatic functions by various neuropeptides.

THYROTROPIN RELEASING HORMONE (TRH)

TRH exists in the central nervous system and abundant TRH immunoreactive nerve terminals and TRH receptors are localized in the dorsal vagal complex including the vagal motor nucleus and the nucleus of the solitary truct[14,15]. Neuropharmachological studies demonstrated that TRH displayed a vast array of central nervous system-mediated actions unrelated to its physiological roel in the regulation of the pituitary thyroid axis[16]. TRH injected into the cerebrospinal fluid or into specific brain nuclei exerted a variety of behavioral effects. Accumulated evidence also demonstrated that TRH had potent central nervous system mediated stimulatory effects on gastrointestinal secretion, motility and transit, as well as on the development of gastric ulceration in rats and other animals[7,8,17,18] Mapping studies using microinjection of TRH or TRH analogs into selective nuclei have identified brain sites important for stimulation of gastric secretion and motility. The gastric secretory response has been elicited by microinjection of TRH into the lateral and the ventromedial hypothalamus[19]. More sensitive sites have been identified in the brainstem including the dorsal vagal complex, the nucleus ambiguus and the raphe pallidus[20-22].

Hepatic blood flow is composed of hepatic arterial and hepatic portal blood supplies. In rats portal blood flow constitutes 80% of hepatic circulation. Portal blood flow was altered by electrical stimulation of autonomic nerves and specific brain nuclei which are important sites for autonomic nervous regulation[23]. Stimulation of sympathetic nerves caused constriction of hepatic arterial and portal vessels, resulting in a decrease of liver blood volume and flow in hepatic artery, and an increase in portal pressure[24]. Electrical stimulation of the hypothalamus produced changes in intestinal blood flow and, consequently, in portal vein and in intrahepatic arterial and portal beds[25]. Moreover, stimulation of the medial and posterior hypothalamus has been reported to increase hepatic arterial resistance and decrease portal blood flow through sympathetic nerves[26]. On the other hand, using an in vivo microscopic technique in rats, dilatation of the liver sinusoid following electrical vagal stimulation and acetylcholine application has been observed[27,28].

We studied the effect of central TRH analog on hepatic microcirculation in anesthetized rats[29]. We used the stable TRH analog, RX 77368, which has the same receptor affinity and about the times the potency of natural TRH. In rats under urethan anesthesia, hepatic microcirculation was assessed by the hydrogengas clearance method. Intracisternal injection (the injection into the cisternal magna of the brain) of TRH analog induced stimulation of hepatic blood flow by 17%-74% in a dose dependent manner ranging from 5 ng to 100 ng. This stimulatory response of hepatic blood flow to central TRH analog occurred during the first 15-min observation period, reached a plateau at 30 min and returned to basal value at 60 min. On the other hand, intravenous injection of the TRH analog did not modify hepatic blood flow, confirming the central but not peripheral action of the TRH analog. Although this increased hepatic blood flow by central TRH analog was not modified by spinal cord transection, it was reversed by atropine, vagotomy, and N-G-nitro-L-arginine methyl ester, an inhibitor of nitric oxide and indomethacin, indicating that TRH acted in the brain to stimulate hepatic blood flow through vagal, muscarinic, prostaglandin and nitric oxide pathways. Mapping studies by microinjection of TRH analog into the medullary nuclei revealed that the left but not right dorsal vagal complex was a responsive site for TRH on modulation of hepatic blood flow[30]. This finding agreed well with anatomical evidence that hepatic vagal nerve is originated in the left, but not right, dorsal vagal complex[13].

Although in adult animals the liver is normally in a state of growth arrest, once the liver is damaged or impaired because of hepatic injury or liver resection, hepatic regeneration or proliferation is immediately started. Seventy percent partial hepatectomy[31] performed in rats initiated a very striking response in the liver remnant through hypertrophy and hyperplasia, and returned to its original size in 7-10 d[31]. Hepatocytes in the non stimulated liver were essentially arrested in the G₀ state. After partial hepatectomy, growth related events started almost instantly as the cells underwent the transition from G₀ to G₁ state(prereplicative phase), which lasted about 12 h, at which point DNA synthesis (S state) began and peaked at about 24 h. Mitosis a similar course 6-8 h later[32]. Many factors, such as hormones, peptides and cytokines, were thought to be involved and may interact synergistically to initiate and maintain hepatic proliferation. The autonomic nervous system was also suggested to play a role in the liver regeneration and regulation of hormones and growth factors related to hepatic proliferation. Partial hepatectomy suppressed the sympathetic nerve activity[33] and plasma adrenaline and noradrenaline increased immediately after partial hepatectomy and α-blockade reversed DNA synthesis induced by hepatectomy[34,35], indicating the involvement of an adrenergic effect on hepatic regeneration. The parasympathetic nervous system was also suggested to play an important role in hepatic proliferation. Subdiaphragmatic vagotomy more strongly suppressed DNA synthesis after partial hepatectomyas compared with the splanchnicectomy[36], and selective hepatic branch vagotomy suppressed or delayed liver regeneration in partially hepatectomized rats[37]. Moreover, lesion of the ventromedial hypothalamus has recently induced hepatic DNA synthesis through the vagal nerve[38].

The effect of central administration of TRH analog, RX 77368, on hepatic proliferation has recently been studied in conscious adult rats[39], because central TRH was known to activate vagal efferent fibers[40,41]. Rats was injected with TRH analog intracisternally and hepatic DNA synthesis was assessed by thymidine incorporation into the hepatic DNA fraction and BrdU accumulation 6-72 h later. Hepatic proliferation was stimulated by intracisternal TRH analog (10 ng) with a peak response at 48 h after peptide injection and returned to basal at 72 h. This stimulatory effect by central TRH on hepatic proliferation was dose related, ranging from 5 ng to 100 ng assessed at 24 h. Intravenous TRH analog did not influence hepatic proliferation, confirming a central but not peripheral action of TRH. Stimulation of hepatic proliferation by central TRH was abolished by hepatic branch vagotomy, atropine and indomethacin, suggesting that TRH acts in the brain to stimulate hepatic proliferation through vagal, muscarinic and prostaglandin pathways. However, N-G-nitro-L-arginine methyl ester did not reverse central TRH induced stimulation of hepatic proliferation as it did central TRH induced hepatic circulation, indicating that stimulation of hepatic proliferation is not secondary to the change in hepatic circulation. These data suggest that TRH in the central nervous system may be involved in the vagal regulation of hepatic proliferation.

These findings led us to speculate that central TRH might also protect against experimental liver damage, so effect of central injection of TRH on CCl₄ induced liver injury has been investigated[42]. Rats were coadministered CCl₄ (2 mL/kg, ip) with TRH analog injected intracisternally and liver damage was assessed by serum alanine aminotransferase (ALT) levels. Intracisternal, bnt not intravenous, injection of TRH analog dose-dependently protected against CCl₄ induced liver damage and this protective effect of central TRH was also block by hepatic vagotomy.

CORTICOTROPIN RELEASING FACTOR (CRF)

CRF is one of the brain neuropeptides, and effect of central CRF on physiological, pharmacological, and pathophysiological regulations of the gastrointestinal tract have been reported. Injection of CRF into the cerebrospinal fluid or the brain nuclei, such as paraventricular nucleus or loecus ceruleus inhibited gastric motility and secretion[43-46], and enhanced colonic motility through the autonomic nervous system[47,48]. Since CRF is known to act in the hypothalamus and stimulate the sympathetic nervous outflow, the opposite effect to TRH on hepatic function was expected when injected in the central nervous system.

We studied the effect of central CRF on hepatic microcirculation in anesthetized rats[49]. In rats under urethan anesthesia, hepatic microcirculation was assessed by the hydrogen gas clearance method and laser Doppler. Intracisternal injection of CRF induced inhibition of hepatic blood flow by 18%-36% in a dose dependent manner, ranging from 1 μg to 5 μg. This inhibitory response of hepatic blood flow to central CRF was noted during the first 15 min observation period, reached a plateau at 30-60 min and maintained for more than 120 min. On the other hand, intravenous injection of the CRF did not modify hepatic blood flow, confirming the central but not peripheral action of the TRH analog. Although this deceased hepatic blood flow by central CRF was not modified by atropine and vagotomy, it was reversed by hepatic sympathectomy and 6-hydroxydopamine, which depleted noradrenergic fibers, indicating that CRF acted in the brain to inhibit hepatic blood flow through sympathetic and noradrenergic pathways. The effect of central injection of CRF on CCl₄ induced liver injury has also been investigated[50]. Rats were injected with CCl₄ (2 mL/kg, sc) and CRF was injected just before and 6 h after CCl₄ administration. Liver damage was assessed by serum ALT levels. Intracisternal, injection of CRF dose dependently aggravated CCl₄ induced liver damage and this aggravating effect of central CRF was block by 6-hydroxydopamine and chemical sympathectomy.

NEUROPEPTIDE Y (NPY)

NPY, a 36 amino acid peptide of the pancreatic polypeptide family, was first isolated from porcine brain[51,52]. NPY was localized mainly in the peripheral nervous system[53], where it contributed to the innervation of the digestive organs, including the biliary tree[54]. In the brain, NPY nerve fibers and terminals, and NPY receptors were localized in the paraventricular nucleus of the hypothalamus and the dorsal vagal complex[55-57] which are important sites for the autonomic nervous system[58]. Central administration of NPY affected feeding behavior and visceral function[57]. The bile duct was richly innervated by autonomic nerves[59] and electrical stimulation of sympathetic and parasympathetic nerves and stimulation or lesion of certain hypothalamic regions[60] altered bile secretion[61,62]. With respect to the gastrointestinal tract, injection of NPY into the cerebrospinal fluid stimulates gastric acid and pepsin secretion, and pancreatic exocrine and endocrine secretion in rats and dogs[63-65]. Farouk et al[66] and we[67] have found an effect of central NPY on bile secretion in dogs and rats. The effect of intracisternal injection of NPY on bile secretion in urethan anesthetized rats was investigated[67]. Rats were anesthetized with urethan (1.5 g/kg, ip) and the common bile duct was cannulated to collect bile samples. Sodium taurocholic acid (30 μmol·kg·h) was infused intravenously to compensate for bile acid loss due to biliary drainage. Intracisternal NPY (0.02 nmol-0.12 nmol) dose-dependently stimulated bile secretion by 9%-20%. The secretory response occurred within the first 20-40 min after injection and lasted 120 min. On the other hand, intravenous injection of NPY (0.12 nmol) did not modify bile secretion, confirming that NPY did not leak from the cerebrospinal fluid to the peripheral circulation. Thus, central NPY stimulated bile secretion in a bile acid independent and bicarbonate dependent bile flow because central NPY increased only biliary bicarbonate secretion but not biliary bile acid, phospholipid or cholesterol secretion. In other words, central NPY stimulated ductal bile secretion. Although cervical cord transection, bilateral adrenalectomy or pretreatment with N-G-nitro-L-arginine methyl ester did not alter intracisternal NPY induced stimulation of bile secretion, atropine and bilateral cervical vagotomy completely abolished the stimulatory effect of intracisternal NPY on bile secretion, indicating that NPY acted in the brain to stimulate bile acid independent bile secretion through vagal and muscarinic pathways. Mapping studies by microinjection of NPY into the medullary nuclei have shown that the left dorsal vagal complex is a responsive site, like TRH on hepatic circulation, for NPY on stimulation of bile secretion[68].

OTHER NEUROPEPTIDES

Besides TRH, CRF and NPY, a few peptides were suggested to act in the central nervous system to modulate hepatobiliary function. β-endorphin has produced 70% inhibition in liver DNA synthesis in six day old rats[69]. Intracerebroventricular injection of bombesin with a dose of 10 μg induces bicarbonate dependent inhibition of bile secretion in rats[70]. Moreover, intracisternal injection of opioid peptide, DAla-Met enkephalinamide decreased bile secretion in urethan anesthetized rats[71].

SUMMARY AND CONCLUSIONS

Several peptides have been established to act in the brain to influence hepatic function (Figure 1). Bile secretion is modified by central administration of bombesin, opioid peptide and NPY, hepatic blood flow is altered by central CRF and TRH, hepatic proliferation is regulated by central β-endorphin and TRH, and central CRF and TRH interfere experimental liver injury. Among these peptides central TRH is the strongest candidate for playing an important role in hepatic physiological function. Through their use, new knowledge on central and peripheral mechanisms underlying brain regulation of hepatic function will be revealed. Further studies in regard to the physiological relevance of the central action of neuropeptides on specific brain sites should be performed for unraveling the underlying pathways mediating brain liver interaction.

Figure 1 Schematic illustration of interaction bween neuropeptides in the central nervous system and hepatobiliary function.

ACKNOWLEDGEMENT

This work was supported by Japan Research Foundation for Clinical Pharmacology, the Akiyama Foundation, Kanae Memorial Foundation and the Ministry of Education, Culture and Science of Japan (No. 0767554, No. 09670503).